LYL1 and myelodysplastic syndrome: Downregulation of endogenous expression of LYL1 in K562 cells by a combination of 3 specific siRNAs could inhibit cellular growth and clonogenicity to some extent, as concluded in the study by Meng et al. It was also postulated in that study that aberrant expression of LYL1 in MDS and AML played a role in the development and phenotype of the diseases by altering the differentiation potential of the cells, increasing the growth rate and plating efficiency of AML cells, and reducing the drug sensitivity.